J&J's RYBREVANT FASPRO posts 77% response rate in first-line head and neck cancer

Johnson & Johnson said on 25 October 2026 that its subcutaneous RYBREVANT FASPRO regimen, amivantamab combined with hyaluronidase-lpuj, produced a confirmed overall response rate of 77% in first-line advanced head and neck cancer ^[1]. The company said the results support continued evaluation of the regimen in an ongoing first-line Phase 3 study ^[1].

The regimen's pitch is its mechanism and its route. It pairs EGFR and MET targeting in a single subcutaneous treatment, and J&J holds US FDA Priority Review for it in advanced head and neck cancer as a potential first-in-class EGFR- and MET-targeted subcutaneous option ^[2].

One distinction matters before anyone reads the 77% as near-term approval leverage. The Priority Review and this readout are not the same program. In May 2026, Janssen announced pivotal Phase 1b/2 OrigAMI-4 results in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy, and submitted a supplemental Biologics License Application to the FDA ^[5].

What a competitor can act on is when a decision lands. Priority Review compresses the FDA's review goal to roughly six months from acceptance. J&J has not published a target action date in the materials Prognyx reviewed, and the dossier does not state the exact date the review clock started, so treat that window as Prognyx's estimate rather than a company figure.

The approved label today is narrower than the head and neck headlines suggest. RYBREVANT FASPRO is cleared in combination with lazertinib for first-line EGFR exon 19 deletion or exon 21 L858R locally advanced or metastatic non-small cell lung cancer ^[4]. Head and neck cancer sits in the regulatory pipeline, under review in the pretreated setting and in Phase 3 in the first-line setting, approved in neither yet.

For an operator with an EGFR/MET asset or a head and neck program, three moves are on the table. Re-baseline comparator assumptions: a subcutaneous regimen posting 77% ORR in untreated disease resets what a new entrant has to beat, if the Phase 3 confirms it. Track the Phase 3 design for its control arm and biomarker criteria, neither disclosed in this release, because those define who the regimen is actually positioned against. And read the January-window FDA decision in the pretreated indication as the near-term proof point for the mechanism in head and neck, ahead of any first-line data.

Neither J&J's release nor Halozyme's filing gives a ClinicalTrials.gov identifier for the Phase 3 study or for OrigAMI-4. And no published FDA target action date is in the materials Prognyx reviewed.

Verdict: a credible first-line efficacy signal that still needs Phase 3 confirmation before it changes practice. Threat to competing EGFR/MET and head and neck programs is moderate and dated; the first hard proof point is the FDA decision in the pretreated indication inside Prognyx's late-January-2027 window, with the first-line Phase 3 the larger, later catalyst.